These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24868526)

  • 1. Stereotactic ablative radiotherapy for oligometastatic disease in liver.
    Kim M; Son SH; Won YK; Kay CS
    Biomed Res Int; 2014; 2014():340478. PubMed ID: 24868526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.
    Comito T; Cozzi L; Clerici E; Campisi MC; Liardo RL; Navarria P; Ascolese A; Tozzi A; Iftode C; De Rose F; Villa E; Personeni N; Rimassa L; Santoro A; Fogliata A; Mancosu P; Tomatis S; Scorsetti M
    BMC Cancer; 2014 Aug; 14():619. PubMed ID: 25163798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of split-course stereotactic ablative radiotherapy for oligometastases.
    Paik EK; Kim MS; Seo YS; Jang WI; Kang JK; Cho CK; Yoo HJ
    Jpn J Clin Oncol; 2018 Jun; 48(6):548-554. PubMed ID: 29722825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
    Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
    Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of stereotactic radiotherapy in the treatment of oligometastatic colorectal cancer].
    Pouypoudat C; Trouette R; Bernard B; Vendrely V
    Cancer Radiother; 2021 Oct; 25(6-7):523-525. PubMed ID: 34454836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors.
    Clerici E; Comito T; Franzese C; Di Brina L; Tozzi A; Iftode C; Navarria P; Mancosu P; Reggiori G; Tomatis S; Scorsetti M
    Strahlenther Onkol; 2020 Apr; 196(4):325-333. PubMed ID: 31605163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review.
    Gouveia AG; Chan DCW; Hoskin PJ; Marta GN; Trippa F; Maranzano E; Chow E; Silva MF
    Radiother Oncol; 2021 Oct; 163():55-67. PubMed ID: 34333087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic ablative radiotherapy for colorectal cancer liver metastasis.
    Wang H; Li X; Peng R; Wang Y; Wang J
    Semin Cancer Biol; 2021 Jun; 71():21-32. PubMed ID: 32629077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer.
    Takeda A; Sanuki N; Kunieda E
    World J Gastroenterol; 2014 Apr; 20(15):4220-9. PubMed ID: 24764660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
    Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
    BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study protocol of the LARK (TROG 17.03) clinical trial: a phase II trial investigating the dosimetric impact of Liver Ablative Radiotherapy using Kilovoltage intrafraction monitoring.
    Lee YYD; Nguyen DT; Moodie T; O'Brien R; McMaster A; Hickey A; Pritchard N; Poulsen P; Tabaksblat EM; Weber B; Worm E; Pryor D; Chu J; Hardcastle N; Booth J; Gebski V; Wang T; Keall P
    BMC Cancer; 2021 May; 21(1):494. PubMed ID: 33941111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Efficacy of Colorectal Cancer Patients with Pulmonary Oligometastases by Sterotactic Body Ablative Radiotherapy: A Meta-Analysis.
    Jeong JU; Rim CH; Yoo GS; Cho WK; Chie EK; Ahn YC; Lee JH;
    Cancer Res Treat; 2024 Jul; 56(3):809-824. PubMed ID: 38097919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy for oligometastases.
    Tree AC; Khoo VS; Eeles RA; Ahmed M; Dearnaley DP; Hawkins MA; Huddart RA; Nutting CM; Ostler PJ; van As NJ
    Lancet Oncol; 2013 Jan; 14(1):e28-37. PubMed ID: 23276369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases.
    Folkert MR; Meyer JJ; Aguilera TA; Yokoo T; Sanford NN; Rule WG; Mansour J; Yopp A; Polanco P; Hannan R; Nedzi LA; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1387-1395. PubMed ID: 33340601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robotic stereotactic radiotherapy for liver oligometastases from colorectal cancer: a single-center experience.
    Vernaleone M; Bonomo P; Di Cataldo V; Saieva C; Masi L; Desideri I; Greto D; Francolini G; Becherini C; Livi L
    Radiol Med; 2019 Sep; 124(9):870-876. PubMed ID: 31104277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review.
    Kobiela J; Spychalski P; Marvaso G; Ciardo D; Dell'Acqua V; Kraja F; Błażyńska-Spychalska A; Łachiński AJ; Surgo A; Glynne-Jones R; Jereczek-Fossa BA
    Crit Rev Oncol Hematol; 2018 Sep; 129():91-101. PubMed ID: 30097241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
    Olson R; Mathews L; Liu M; Schellenberg D; Mou B; Berrang T; Harrow S; Correa RJM; Bhat V; Pai H; Mohamed I; Miller S; Schneiders F; Laba J; Wilke D; Senthi S; Louie AV; Swaminath A; Chalmers A; Gaede S; Warner A; de Gruijl TD; Allan A; Palma DA
    BMC Cancer; 2020 May; 20(1):380. PubMed ID: 32370765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial.
    Mercier C; Claessens M; Buys MSc A; Gryshkevych S; Billiet C; Joye I; Van Laere S; Vermeulen P; Meijnders P; Löfman F; Poortmans P; Dirix L; Verellen D; Dirix P
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1195-1205. PubMed ID: 33307151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of hepatic oligometastases with stereotactic ablative radiotherapy and radiofrequency ablation in an anaplastic lymphoma kinase fusion-positive lung cancer patient.
    Weber B; Liu M; Sobkin P; Morris SW; Hout D; van der Westhuizen N; Tonseth RP; Saltman DL
    J Med Radiat Sci; 2016 Mar; 63(1):67-70. PubMed ID: 27087977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma.
    Jin H; Chalkidou A; Hawkins M; Summers J; Eddy S; Peacock JL; Coker B; Kartha MR; Good J; Pennington M;
    Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e143-e154. PubMed ID: 32951952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.